| Autor: |
Ramalho, Ízola Morais de Medeiros, Pereira, Daniel Torres, Galvão, Giovanna Brunelly Lima, Freire, Danielle Teixeira, Amaral-Machado, Lucas, Alencar, Éverton do Nascimento, Egito, Eryvaldo Socrates Tabosa do |
| Zdroj: |
Expert Opinion on Drug Delivery; November 2021, Vol. 18 Issue: 11 p1577-1587, 11p |
| Abstrakt: |
ABSTRACTIntroductionCannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective.Areas coveredThis review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use.Expert opinionStudies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
